LeMaitre Vascular (NASDAQ:LMAT) Releases FY 2024 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its FY 2024 earnings guidance on Friday morning. The company provided EPS guidance of 1.730-1.840 for the period, compared to the consensus EPS estimate of 1.650. The company issued revenue guidance of $212.7 million-$217.3 million, compared to the consensus revenue estimate of $211.7 million. LeMaitre Vascular also updated its Q2 2024 guidance to 0.450-0.500 EPS.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on LMAT shares. JMP Securities boosted their price objective on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a market outperform rating in a report on Friday. Barrington Research raised their price objective on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an outperform rating in a research note on Friday. KeyCorp assumed coverage on LeMaitre Vascular in a research report on Tuesday, February 6th. They set a sector weight rating for the company. StockNews.com upgraded LeMaitre Vascular from a hold rating to a buy rating in a research report on Friday. Finally, Stifel Nicolaus upgraded shares of LeMaitre Vascular from a hold rating to a buy rating and increased their price objective for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $73.83.

LeMaitre Vascular Stock Up 11.2 %

NASDAQ:LMAT opened at $74.22 on Monday. The firm has a market capitalization of $1.67 billion, a PE ratio of 49.15, a price-to-earnings-growth ratio of 2.99 and a beta of 0.88. LeMaitre Vascular has a twelve month low of $44.27 and a twelve month high of $74.64. The stock’s 50-day simple moving average is $65.93 and its 200 day simple moving average is $58.85.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. The company had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period last year, the company posted $0.27 EPS. On average, analysts anticipate that LeMaitre Vascular will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 30th. Investors of record on Thursday, May 16th will be issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is 42.38%.

Insider Buying and Selling

In related news, Director Lawrence J. Jasinski sold 5,110 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the transaction, the director now owns 5,309 shares in the company, valued at approximately $358,357.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other LeMaitre Vascular news, Director John A. Roush sold 7,500 shares of the company’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $69.00, for a total value of $517,500.00. Following the sale, the director now owns 2,278 shares in the company, valued at approximately $157,182. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Lawrence J. Jasinski sold 5,110 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total value of $344,925.00. Following the completion of the sale, the director now directly owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The disclosure for this sale can be found here. Insiders have sold 114,036 shares of company stock worth $7,873,749 in the last 90 days. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.